ATRA | Jotup

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Retrieved on:

Wednesday, November 8, 2023

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS).
The study did not meet the primary endpoint of confirmed disability improvement (CDI) by expanded disability status scale (EDSS) at 12 months compared to placebo.
In addition, fluid and imaging biomarkers did not provide further supportive evidence.
"We are surprised and deeply disappointed with the results of EMBOLD, particularly for the MS patient community which is in urgent need of new treatment options.

Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

Retrieved on:

Wednesday, November 1, 2023

Key Points:

“We are proud to expand our global tab-cel partnership with Pierre Fabre Laboratories, who is committed to delivering this first-of-its-kind treatment to patients in need across the globe,” said Pascal Touchon, President and Chief Executive Officer of Atara.
In addition, Pierre Fabre Laboratories has agreed to reimburse Atara for expected tab-cel global development costs through Biologics License Application (BLA) transfer, and purchase current and future tab-cel inventory through the BLA transfer date.
PJT Partners served as the exclusive financial advisor to Atara and Fenwick & West LLP served as legal counsel to Atara.
Concurrent with the execution of the global tab-cel partnership, Atara is undertaking a strategic restructuring and is reducing its current workforce by approximately 30 percent.

HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma

Retrieved on:

Monday, October 23, 2023

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ATRA, Survival, MDSC, Myeloid-derived suppressor cell, B cell, Partnering, Tumor microenvironment, Safety, Cancer, Patient, Myelocyte, Glioma, Pharmaceutical industry

Key Points:

“These encouraging results show HF1K16 is well tolerated and patients have experienced significant disease control,” said Yuhong Xu, CEO of HighField.
One of the other two patients, with grade IV glioblastoma, maintained stable disease for more than 4 months.
The third patient had stable disease for nearly 3 months and survival to date for more than 9 months.
The Phase 1b/2 trial, underway in China, and will assess safety and efficacy as well as evaluate changes in MDSC numbers and phenotypes.

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, October 6, 2023

Oncology, Health, Stem Cells, Other Health, General Health, Pharmaceutical, Biotechnology, EBV, Northwest Biotherapeutics, Employment, Epstein–Barr virus, Compensated emancipation, Patient, Cancer, ATRA, Pharmaceutical industry, Thermoplastic

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 56,750 restricted stock units of Atara’s common stock to four newly hired employees.
These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of October 2, 2023, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability

Retrieved on:

Tuesday, September 19, 2023

Key Points:

Following productive discussions between Atara and the U.S. Food and Drug Administration (FDA), the FDA and Atara are now aligned on analytical comparability between manufacturing process versions.
This alignment supports Atara's ability to pool the pivotal clinical trial data from different process versions in the Biologics License Application (BLA) submission.
Atara expects to submit the tab-cel BLA in Q2 2024, which will enable Atara to incorporate the latest tab-cel pivotal trial data from the ALLELE study into the BLA filing package.
Tabelecleucel is commercialized by Pierre Fabre in Europe as EBVALLO™ following European Commission marketing authorization in December 2022.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, September 1, 2023

Biotechnology, Health, Stem Cells, Pharmaceutical, Oncology, ATRA, Northwest Biotherapeutics, Cancer, Employment, Epstein–Barr virus, Patient, EBV, Compensated emancipation, Pharmaceutical industry, Thermoplastic

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,250 restricted stock units of Atara’s common stock to one newly hired employee.
This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of September 1, 2023, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference

Retrieved on:

Thursday, August 31, 2023

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a Cell Therapies in Autoimmune panel discussion at the Citi 18th Annual BioPharma Conference on Thursday, September 7, 2023 at 10:50 a.m. PDT / 1:50 p.m. EDT.
A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com .
An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress

Retrieved on:

Tuesday, August 8, 2023

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, recent business highlights and key upcoming catalysts.
“We are pleased to announce IND clearance for ATA3219, our first allogeneic CAR-T cell product candidate expected to enter the clinic in the coming months as a potential best-in-class treatment for patients with certain B-cell malignancies,” said Pascal Touchon, President and Chief Executive Officer of Atara.
Second quarter 2022 net income included $50.9 million of deferred revenue recognized due to the termination of the Bayer Collaboration Agreements and a gain on the sale of the ATOM facility of $50.2 million.
Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $13.8 million for the second quarter 2023, as compared to $15.6 million for the same period in 2022
Research and development expenses were $56.1 million for the second quarter 2023, as compared to $64.9 million for the same period in 2022
General and administrative expenses were $13.3 million for the second quarter 2023, as compared to $18.8 million for the same period in 2022
General and administrative expenses include $5.4 million of non-cash stock-based compensation expenses for the second quarter 2023, as compared to $6.2 million for the same period in 2022

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, August 4, 2023

Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, ATRA, Northwest Biotherapeutics, Cancer, Employment, Epstein–Barr virus, Patient, EBV, Compensated emancipation, Vaccine, Thermoplastic, Pharmaceutical industry

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 72,000 restricted stock units of Atara’s common stock to two newly hired employees.
These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of August 1, 2023, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Retrieved on:

Tuesday, August 1, 2023

Biotechnology, General Health, Health, ATRA, Northwest Biotherapeutics, Cancer, Epstein–Barr virus, Patient, EBV, Vaccine

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023.